Working... Menu
Trial record 15 of 277 for:    Non-alcoholic Steatohepatitis | United States

Colesevelam Versus Placebo in the Treatment of Nonalcoholic Steatohepatitis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01066364
Recruitment Status : Unknown
Verified February 2010 by University of California, San Diego.
Recruitment status was:  Enrolling by invitation
First Posted : February 10, 2010
Last Update Posted : February 10, 2010
Daiichi Sankyo, Inc.
Information provided by:
University of California, San Diego

Brief Summary:
The purpose of the study is to see if the drug colesevelam is a potential treatment for Nonalcoholic Steatohepatitis(NASH).

Condition or disease Intervention/treatment Phase
Nonalcoholic Steatohepatitis Drug: Colesevelam Hcl Phase 2

Detailed Description:

We plan to investigate the role of colesevelam, a bile-acid binding resin, in patients with NASH residing in the United States and assess liver fat changes during therapy using MRI of the liver. It can be hypothesized that colesevelam would lead to a greater improvement in insulin sensitivity and lipid profile compared with placebo and may lead to greater improvement in liver fat by MRI as compared to placebo.

In this pilot study, we propose to randomize approximately 55 patients (1:1 ratio) to either colesevelam or placebo and treat them for 24-weeks to evaluate changes in baseline insulin sensitivity, serum biochemistry (ALT and AST), and liver fat by MRI during therapy. Liver histologic changes would also be examined as an exploratory outcome for future studies.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 54 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Colesevelam Versus Placebo in the Treatment of Nonalcoholic Steatohepatitis
Study Start Date : February 2010
Estimated Primary Completion Date : February 2012
Estimated Study Completion Date : February 2012

Arm Intervention/treatment
Placebo Comparator: Placebo (sugar) pill
Six tablets per day (identical to colesevelam)
Drug: Colesevelam Hcl
3.75 gm/day (six 675 mg tablets)
Other Name: Welchol

Experimental: Colesevelam arm
3.75 grams per day
Drug: Colesevelam Hcl
3.75 gm/day (six 675 mg tablets)
Other Name: Welchol

Primary Outcome Measures :
  1. The primary outcome will be improvement in hepatic steatosis by liver MRI [ Time Frame: 24 weeks ]

Secondary Outcome Measures :
  1. Insulin sensitivity as determined by HOMA-IR [ Time Frame: 24 weeks ]
  2. Serum ALT and AST values [ Time Frame: 24 weeks ]
  3. Lipid profiles [ Time Frame: 24 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Age at entry at least 18 years.
  2. Serum alanine (ALT) or aspartate (AST) aminotransferase activities that are above the upper limits of normal. 19 or more in women and 30 or more in men.
  3. Evidence of hepatic steatosis or liver fat (>5%) by MRI.
  4. Evidence of definite or suspected NASH
  5. Written informed consent.

Exclusion criteria:

  1. Evidence of another form of liver disease.
  2. History of excess alcohol ingestion.
  3. Contraindications to liver biopsy.
  4. Decompensated liver disease.
  5. History of gastrointestinal bypass surgery or ingestion of drugs known to produce hepatic steatosis.
  6. Recent initiation or change of anti-diabetic drugs.
  7. Use of colesevelam or other agents in the same class.
  8. Significant systemic or major illnesses other than liver disease that, in the opinion of the investigator would preclude treatment with colesevelam and adequate follow up.
  9. Positive test for anti-HIV.
  10. Active substance abuse, such as alcohol, inhaled or injection drugs within the previous one year.
  11. Pregnancy or inability to practice adequate contraception in women of childbearing potential.
  12. Evidence of hepatocellular carcinoma

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01066364

Layout table for location information
United States, California
UCSD: Prevention Studies Clinic
La Jolla, California, United States, 92093
UCSD: Medical Center- Hillcrest
San Diego, California, United States, 92103
Sponsors and Collaborators
University of California, San Diego
Daiichi Sankyo, Inc.
Layout table for investigator information
Principal Investigator: Rohit Loomba, MD, M.H.Sc University of California, San Diego

Layout table for additonal information
Responsible Party: Rohit Loomba, MD, M.H.Sc, UCSD: Gastroenterology- Dept of Medicine, Epidemiology- Dept of Family and Preventive Medicine Identifier: NCT01066364     History of Changes
Other Study ID Numbers: 091491
First Posted: February 10, 2010    Key Record Dates
Last Update Posted: February 10, 2010
Last Verified: February 2010

Keywords provided by University of California, San Diego:
Fatty Liver Disease

Additional relevant MeSH terms:
Layout table for MeSH terms
Fatty Liver
Non-alcoholic Fatty Liver Disease
Liver Diseases
Digestive System Diseases
Colesevelam Hydrochloride
Anticholesteremic Agents
Hypolipidemic Agents
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents